Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
The latest first-in-human trial entrants include several novel mechanisms, a PSMA radioconjugate and a new pan-KRAS challenger.
Phase 1 data suggest the group’s KRAS G12C inhibitor has activity, crucially in KRAS-experienced patients.
Initial data on Amgen’s AMG 193 give some Tango investors a headache.
The company’s FGFR2 inhibitor shows potential beyond cholangiocarcinoma, but the markets aren’t buying it.
Data on PMV’s p53 reactivator prompt a 26% selloff before their presentation, and 48% afterwards.
Tempest Therapeutics confirms an earlier success with its lead project, and this time investors respond.